Le Lézard
Classified in: Health
Subjects: FVT, MAT

Trulieve Announces December 2022 Event Participation


TALLAHASSEE, Fla., Dec. 1, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned participation in upcoming conferences and events in December.

Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events-presentations

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve_ 
Twitter: @Trulieve 

Investor Contact
Christine Hersey, Executive Director of Investor Relations
+1 (424) 202-0210
[email protected]

Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
[email protected]

SOURCE Trulieve Cannabis Corp.


These press releases may also interest you

at 23:17
LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

at 20:07
Ascentage Pharma Received US$100 Million Option Payment from Takeda
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

at 20:00
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...

at 19:54
British Columbia designates Psychotherapy under the Health Professions Act
On July 02, 2024, the BC Government designated Psychotherapy as a Health Profession under the Health Professions Act. The proposal received cabinet approval and was subsequently signed by the Lieutenant Governor. The official order can be viewed...

at 19:52
Whitman-Walker Institute Condemns Nationwide Injunction Blocking Federal Nondiscrimination Protections for Transgender People Following a 'Shameful' Decision in Tennessee Case
Whitman-Walker Institute condemns the politically motivated ruling from a federal district court judge that blocks vital nondiscrimination protections for transgender people across the country. Today, a U.S. district court judge in Mississippi issued...

at 19:22
Baixiang brand Instant Noodles recalled due to undeclared peanut
Product: Instant Noodle Issue: Food - Allergen - Peanut Distribution: AlbertaBritish ColumbiaOntario See the affected products and product photos for this recall Company information Five Continents International Ltd. Telephone: 416-292-6766| Fax:...

More news about Health...


News published on and distributed by: